<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../k34gmbu8.html">Pocket Medicine
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0013.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0015.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h111" class="calibre7"></a><a id="page_9-1" class="calibre7"></a><a href="part0002.html#rh123" class="calibre7">CHANGE IN MENTAL STATUS</a></h2>
<p class="h2a">Consciousness/Arousal <span class="s">(description of patient &amp; timing is most helpful)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Arousal:</b> spectrum from awake/alert → drowsy → stupor → coma. Terms vague &amp; subjective, so most useful to describe response to increasing stimulation (eg, voice → noxious).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Coma:</b> lack of response to external stimuli. Degree formalized in Glasgow Coma Scale. Caused by focal lesions in brainstem (reticular activating system), thalamus, or diffuse dysfxn of both cerebral hemispheres. Mimics: locked-in synd., akinetic mutism, catatonia.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Delirium/acute confusional state:</b> altered attention &amp; awareness, develops over hrs to days, often fluctuating, accompanied by cognitive Δs (eg, disorientation, memory loss, perceptual Δs); sometimes w/ sleep–wake dysregulation, autonomic Δs, emotionality</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dementia:</b> progressive cognitive impairment developing over mos to yrs; often affects memory, language, visuospatial and executive function; attention often spared</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre36"/>
<col class="calibre43"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc">Etiologies of Decreased Responsiveness</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">1° Neurologic</b> (<i class="calibre3">usually with focal signs</i>)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Systemic</b> <i class="calibre3">(esp. in elderly or prior CNS injury)</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabh">Vasc: ischemic stroke/TIA, ICH, VST, PRES, vasculitis, pituitary apoplexy</p>
<p class="tabh">Seizure: postictal, status, nonconvulsive</p>
<p class="tabh">Infxn: meningitis, encephalitis, abscess</p>
<p class="tabh">Trauma: TBI, concussion, diffuse axonal injury</p>
<p class="tabh">↑ intracranial pressure: mass, edema, hydrocephalus, herniation</p>
<p class="tabh">Autoimmune/paraneoplastic enceph.</p>
<p class="tabh">Neurodeg: late-stage (eg, Alzheimer’s) or rapidly progressive (eg, CJD)</p></td>
<td class="bg"><p class="tab">Cardiac: global ischemia, HoTN, HTN enceph</p>
<p class="tab">Pulmonary: ↓ PaO2, ↑ PaCO2</p>
<p class="tab">GI: liver failure, ↑ NH3</p>
<p class="tab">Renal: uremia, dialysis, ↓ or ↑ Na, ↓ or ↑ Ca</p>
<p class="tab">Heme: TTP/HUS, DIC, hyperviscosity</p>
<p class="tab">Endo: ↓ glc, DKA/HHNS, hypothyr., Addisonian</p>
<p class="tab">ID: pneumonia, UTI, endocarditis, sepsis</p>
<p class="tab">Hypothermia &amp; hyperthermia</p>
<p class="tab">Meds: anticholin., anti-hist., psychotrop., digoxin</p>
<p class="tab">Toxins/withdrawal: EtOH, sedative, opiate, CO</p>
<p class="tab">Psychiatric: catatonia, serotonin synd., NMS</p></td>
</tr>
</table>
<p class="h2a"><a id="page_9-2" class="calibre1"></a>Initial evaluation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">History</b> (witness &amp; background <i class="calibre3">crucial</i>): tempo, premorbid sx (eg, focal neuro deficits, HA, infxn, pain, falls), medical conditions (eg, dementia, epilepsy, onc, cardiac, psych, infection/immune status), accompanied by head trauma, current meds (eg, sedatives, opioids, anticoag, anticonvulsants, immunosuppressants), drug/alcohol use</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">General exam:</b> <i class="calibre3">VS</i>, breathing pattern (eg, Cheyne-Stokes), tongue bite (seizure), <i class="calibre3">nuchal rigidity</i> (meningitis, SAH; <i class="calibre3">do not test</i> if c/f trauma/cervical spine fx), ecchymoses, rash, signs of head trauma (eg, Battle sign, raccoon eyes, hemotympanum, CSF rhinorrhea), asterixis, liver disease stigmata, embolic phenomena/endocarditis, s/s drug use</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neuro exam</b> (see below): perform off sedatives/paralytics if possible, look for focal deficits suggesting structural cause (eg, stroke, herniation), s/s of ↑ ICP (eg, HA, vomiting, papilledema, abducens nerve palsy, unilateral dilated pupil, ↑ BP/↓ HR, fixed downgaze)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre10"/>
<col class="calibre11"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc">Neuro Exam in Patients with Decreased Responsiveness</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Mental status</p></td>
<td class="bg0-b"><p class="tab">Arousal (behavioral response to ↑ intensity of stimulation, GCS)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Cranial nerves</p></td>
<td class="bg0-b"><p class="tabh">Pupils: <i class="calibre3">pinpoint</i> → opiates, pontine lesion; <i class="calibre3">midposition &amp; fixed</i> → midbrain lesion; <i class="calibre3">fixed &amp; dilated</i> → severe anoxic injury, herniation, anti-cholin.</p>
<p class="tabh">Extraocular movements / vestibulo-ocular reflex tests:</p>
<p class="tabh1">Oculocephalic maneuver (“doll’s eyes”): nl = eyes move opposite head movement (do not test if possible cervical spine trauma)</p>
<p class="tabh1">Vestibular (cold) caloric stimulation: in coma, nl = eyes move slowly to lavaged ear, then quickly away (<i class="calibre3">do not test w tymp memb perf)</i></p>
<p class="tabh">Corneal reflex, facial grimace to nasal tickle</p>
<p class="tabh">Gag &amp; cough reflexes (with ET tube manipulation if necessary)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Motor</p></td>
<td class="bg0-b"><p class="tab">Tone, spont movements, flexor/extensor posturing of arms/legs, strength</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Sensory</p></td>
<td class="bg0-b"><p class="tab">Response to painful stimuli: purposeful vs. reflexive/posturing</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Reflexes</p></td>
<td class="bg"><p class="tab">Deep tendon reflexes, Babinski, “triple” flexion (ankle, knee, &amp; hip flexion to noxious stimulation → not suggestive of intact cortical function)</p></td>
</tr>
</table>
<p class="image1"><img src="../images/00134.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Initial treatment</p>
<p class="bl"><span class="sbl">•</span> Empiric antibiotics if c/f CNS infection: vancomycin/CTX, consider acyclovir and ampicillin</p>
<p class="bl"><span class="sbl">•</span> Immobilization of C-spine if concern for cervical trauma</p>
<p class="bl"><span class="sbl">•</span> Thiamine 100 mg IV → dextrose 50 g IVP (this order to prevent exacerbation of Wernicke’s)</p>
<p class="bl"><span class="sbl">•</span> If opiates suspected: naloxone 0.01 mg/kg; if BDZ suspected, consider flumazenil 0.2mg IV</p>
<p class="bl"><span class="sbl">•</span> If concern for ↑ ICP ± herniation: ↑ head of bed; osmotherapy w/ mannitol or hypertonic saline; ↑ ventilation; dexamethasone for tumor edema; c/s neurosurgery (? decompress)</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">Lancet</i> 2014;384:2064)</span></p>
<p class="bl"><span class="sbl">•</span> All patients: check fingerstick glucose, electrolytes, BUN/Cr, LFTs, CBC, tox screen, U/A</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Based on clinical suspicion:</i></p>
<p class="bl1">Labs: NH<sub class="calibre8">3</sub>, TSH, cort stim, B<sub class="calibre8">12</sub>, ABG, HIV, ESR, ANA, TPO/anti-TG, BCx, drug levels</p>
<p class="bl1">Imaging: head CT, then MRI; CTA if c/f stroke/SAH; radiographs to r/o C-spine fracture</p>
<p class="bl1">Lumbar puncture to r/o meningitis, SAH, or noninfectious inflammation (eg, autoimmune)</p>
<p class="bl1">EEG to evaluate for nonconvulsive seizures, toxic/metabolic encephalopathy</p>
<p class="h2a">Further treatment of delirium <span class="s">(<i class="calibre3">NEJM</i> 2017;377:1456)</span></p>
<p class="bl"><span class="sbl">•</span> Treat underlying acute illness, eliminate precipitating factors, &amp; provide supportive care</p>
<p class="bl"><span class="sbl">•</span> Address sensory &amp; cognitive impairments (frequent reorientation, glasses/hearing aids, etc.)</p>
<p class="bl"><span class="sbl">•</span> Decrease/prevent infection/restraints if possible, remove lines/catheters if unnecessary</p>
<p class="bl"><span class="sbl">•</span> Promote good sleep: reduce noise &amp; nighttime interventions; sedative med if necessary</p>
<p class="bl"><span class="sbl">•</span> Meds: consider antipsychotics (but neither haloperidol nor ziprasidone ↓ delirium duration in ICU Pts; <i class="calibre3">NEJM</i> 2018;379:2506); avoid benzos except in EtOH withdrawal or seizures</p>
<p class="h">A<small class="calibre30">NOXIC</small> B<small class="calibre30">RAIN</small> I<small class="calibre30">NJURY</small> <span class="s4">(at risk if ≥5 min cerebral hypoxia)</span></p>
<p class="h2a">Initial evaluation <span class="s">(<i class="calibre3">Circulation</i> 2010:S768)</span></p>
<p class="bl"><span class="sbl">•</span> Neuro exam: arousal/verbal, eyes &amp; other cranial nerves, motor response to pain</p>
<p class="bl"><span class="sbl">•</span> Imaging: CT usually not informative w/in first day after arrest, but should be done prior to initiating hypothermia if patient found down or has had head trauma</p>
<p class="h2a">Targeted temperature management <span class="s">(<i class="calibre3">Circulation</i> 2015;132:2448)</span></p>
<p class="bl"><span class="sbl">•</span> Indications: comatose (GCS &lt;8) w/in 6h after cardiac arrest (not isolated resp. arrest). Studied only in VT/VF, but consider after asystole or PEA, or 6–12h post-arrest.</p>
<p class="bl"><span class="sbl">•</span> Exclusions: pregnancy, CV instability despite pressors/assist devices, other cause of coma, persistent ↓ O<sub class="calibre8">2</sub>. Relative contraindications: major head trauma, coagulopathy/bleeding, major surgery &lt;14d, systemic infection/sepsis.</p>
<p class="bl"><span class="sbl">•</span> Target temp: 32–36°C × <span class="s">≥</span>24h. Initial studies showing benefit targeted 32–34°C, but subsequent study showed ≈ outcomes for 36°C vs. 33°C <span class="s1r">(<i class="calibre3">NEJM</i> 2013;369:2197)</span>. Some still target 32–34°C and reserve 36°C for Pts w/ contraindic to more aggressive cooling.</p>
<p class="bl"><span class="sbl">•</span> Method: ice packs to head/neck/torso; cooling blankets; cooling vest or endovascular catheter. Goal to achieve target temp &lt;6h (but no benefit to prehosp cooling; <i class="calibre3">JAMA</i> 2014;311:45). Pts should be sedated/paralyzed while cooled. MAP goal &gt;70. Start rewarming 24h after cooling is initiated (rewarm <span class="s">≤</span>0.5°C per h).</p>
<p class="bl"><span class="sbl">•</span> In Pts not cooled or after rewarming Pts who were cooled: prevent fever (goal &lt;36°C) for ≥48h post arrest</p>
<p class="bl"><span class="sbl">•</span> Complications</p>
<p class="bl1">Dysrhythmias (brady most common): if significant or hemodynamic instability → rewarm</p>
<p class="bl1">Coagulopathy (can receive lytics, GP IIb/IIIa inhibitors, etc.); monitor PT &amp; PTT</p>
<p class="bl1">Infection: monitor surveillance blood cultures during cooling</p>
<p class="bl1">Hyperglycemia during cooling, hypoglycemia w/ rewarming; stop insulin if glc &lt;200 mg/dL</p>
<p class="bl1">Hypokalemia during cooling, hyperkalemia w/ rewarming; keep K 4–5 mEq/L</p>
<p class="h2a">Ongoing evaluation</p>
<p class="bl"><span class="sbl">•</span> Neuro exam: daily focus on coma exam. No exam finding is reliable &lt;24 h or on sedation. Should be off sedation for adequate time (depends on dose, duration, Pt’s metabolism).</p>
<p class="bl"><span class="sbl">•</span> Labs: daily CBC, PT/PTT, electrolytes. Serum neuron-specific enolase (NSE) on days 1–3.</p>
<p class="bl"><span class="sbl">•</span> Imaging: noncontrast CT 24 h after arrest; if unrevealing, consider MRI around days 3–5</p>
<p class="bl"><span class="sbl">•</span> EEG: consider in all to exclude seizures; greatest risk during rewarming</p>
<p class="bl"><span class="sbl">•</span> Somatosensory evoked potentials (SSEP): helpful for prediction of poor outcome if cortical responses are absent bilaterally; perform 48 h after arrest (72 h if cooled)</p>
<p class="h2a">Prognosis <span class="s">(<i class="calibre3">Nat Rev Neuro</i> 2014;10:190)</span></p>
<p class="bl"><span class="sbl">•</span> Prior to cooling era, poor prognosis at 72 h if absent pupillary &amp; corneal reflexes and no motor response to pain; or absent SSEPs at 48 h. With cooling, unclear if prior measures as reliable. Overall ~12% survive to hosp. d/c; VT/VF 25-40%, PEA ~10%, asystole ~2%.</p>
<p class="bl"><span class="sbl">•</span> Prognosis requires multifactorial assessment based on age, exam, comorbidities, ancillary data. Poor signs: absent brainstem reflexes, Rx-resistant myoclonus, EEG w/ absent background/reactivity, NSE &gt;33, diffuse hypoxic injury on MRI. If doubt, err on more time.</p>
<h2 class="ct"><a id="h112" class="calibre7"></a><a id="page_9-3" class="calibre7"></a><a href="part0002.html#rh124" class="calibre7">SEIZURES</a></h2>
<p class="h2a">Definitions &amp; clinical manifestations <span class="s">(<i class="calibre3">Epilepsia</i> 2017;58:522)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Seizure:</b> transient neurologic symptoms due to excessive synchronous neuronal activity; may be <i class="calibre3">provoked</i> by a reversible factor lowering the seizure threshold, or <i class="calibre3">unprovoked</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Epilepsy:</b> <span class="s">≥</span>2 unprovoked seizures occurring &gt;24 h apart <i class="calibre3">or</i> 1 unprovoked seizure w/ <span class="s">≥</span>60% probability of further seizures over the next 10 y (see below for prognostication)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Generalized seizures</b> (involves brain diffusely)</p>
<p class="bl1"><i class="calibre3">Tonic-clonic</i> (grand mal):</p>
<p class="bl2"><b class="calibre4">Aura</b> (sec to mins): premonition with paresthesias, focal motor contractions, abnormal smells/tastes, fear, depersonalization, déjà vu, autonomic changes, automatisms</p>
<p class="bl2"><b class="calibre4">Ictal period</b> (sec to mins): lateral gaze and head deviation, tonic contraction of muscles → intermittent relaxing and tensing of muscles, tongue biting, urinary incontinence, pooling of secretions, incontinence</p>
<p class="bl2"><b class="calibre4">Postictal period</b> (mins to h): slowly resolving period of confusion, disorientation, and lethargy. May be accompanied by focal neurologic deficits (Todd’s paralysis).</p>
<p class="bl1"><i class="calibre3">Absence</i> (petit mal): transient lapse of consciousness w/o loss of postural tone, usu pedi</p>
<p class="bl1"><i class="calibre3">Myoclonic</i> (infantile spasms &amp; juvenile myoclonic epilepsy): sudden, brief contraction</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Focal seizures</b> (involves discrete brain area, often associated with a structural lesion)</p>
<p class="bl1"><i class="calibre3">w/o impaired awareness:</i> focal motor/autonomic sx (formerly “simple partial seizure”) or focal sensory/psychic symptoms (eg, aura)</p>
<p class="bl1"><i class="calibre3">w/ impaired awareness:</i> dyscognitive features (formerly “complex partial seizure”)</p>
<p class="bl1"><i class="calibre3">evolving to bilateral, convulsive seizure</i> (formerly “secondarily generalized seizure”)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Status epilepticus:</b> continuous convulsive seizure <span class="s">≥</span>5 min or &gt;2 seizures w/o resolution of postictal encephalopathy; <i class="calibre3">life threatening</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonconvulsive status epilepticus:</b> alteration of awareness (ranging from confusion to coma) w/o motor manifestations of seizure; dx with EEG</p>
<p class="h2a">Differential diagnosis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Syncope</b> <span class="s1r">(<i class="calibre3">Lancet Neurol</i> 2006;5:171)</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre27"/>
<col class="calibre36"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabheadc">Feature</p></td>
<td class="bg1-b"><p class="tabheadc">Seizure</p></td>
<td class="bg1-b"><p class="tabheadc">Syncope</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Aura</p></td>
<td class="bg0-br"><p class="tabc">Unusual behavior/automatisms</p></td>
<td class="bg0-b"><p class="tabc">Diaphoresis, nausea, tunnel vision</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Convulsions</p></td>
<td class="bg0-br"><p class="tabc">Variable duration</p></td>
<td class="bg0-b"><p class="tabc">Usually &lt;10 sec</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Postictal state</p></td>
<td class="bg0-br"><p class="tabc">Yes; can be ≥30 min</p></td>
<td class="bg0-b"><p class="tabc">None or short</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc">Other clues</p></td>
<td class="bg0-r"><p class="tabc">Tongue biting, incontinence</p></td>
<td class="bg"><p class="tabc">Skin pallor, clamminess</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonepileptic seizure</b> (aka “psychogenic”): may see side-to-side head turning, asymmetric large-amplitude limb movements, hip thrusting, diffuse shaking w/o LOC, crying/talking during event; diagnosis requires spell capture on EEG with no EEG correlate</p>
<p class="bl"><span class="sbl">•</span> Other: metabolic disorders (eg, alcoholic blackouts, hypoglycemia), migraine, TIA, transient global amnesia, narcolepsy (cataplexy), nonepileptic myoclonus, tics, asterixis</p>
<p class="h2a">Etiologies of seizures <span class="s">(vary strongly by age)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Without focal lesion:</b> genetic predisposition to seizures or epilepsy syndrome; alcohol withdrawal, illicit drugs; meds (eg, β-lactams, bupropion, fluoroquinolones, tramadol, MNZ, meperidine, CsA); electrolyte (hyponatremia) &amp; other metabolic (eg, uremia, liver failure, hypoglycemia); autoimmune encephalitis, idiopathic (~60%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">With focal lesion:</b> tumor, trauma, stroke, subdural hematomas, posterior reversible encephalopathy syndrome, mesial temporal sclerosis, abscess, focal cortical dysplasia</p>
<p class="h2a">Clinical evaluation <span class="s">(<i class="calibre3">JAMA</i> 2016;316:2657)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">History key in differentiating seizure from other causes of transient loss of consciousness.</i> Must talk to witnesses. Ask about prodrome, unusual behavior before spell, type &amp; pattern of abnl movements incl. head turning &amp; eye deviation (gaze preference usually <i class="calibre3">away</i> from seizure focus), loss of responsiveness.</p>
<p class="bl"><span class="sbl">•</span> Recent events: illnesses/fevers, head trauma, sleep deprivation, stressors</p>
<p class="bl"><span class="sbl">•</span> PMH: prior seizures or ⊕ FHx; prior CNS infection, stroke or head trauma; dementia</p>
<p class="bl"><span class="sbl">•</span> Medications (new or noncompliance), alcohol and illicit drug use</p>
<p class="bl"><span class="sbl">•</span> General physical exam should include the skin, looking for neuroectodermal disorders (eg, neurofibromatosis, tuberous sclerosis) that are a/w seizures</p>
<p class="bl"><span class="sbl">•</span> Neurologic exam should look for focal abnormalities → underlying structural abnormality</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">Neurology</i> 2007;69:1996)</span></p>
<p class="bl"><span class="sbl">•</span> Lab: full lytes, BUN, Cr, glc, LFTs, tox screen, AED levels (valproic acid and phenytoin have therapeutic range; levetiracetam level rarely useful unless ? noncompliance), illicit drug screen</p>
<p class="bl"><span class="sbl">•</span> Routine EEG (~30 min): may help determine risk of seizure recurrence after 1<sup class="calibre15">st</sup>-time unprovoked seizure. Caveat: interictal EEG nl in 50% of Pts w/ epilepsy, and interictal <a id="page_9-4" class="calibre1"></a>epileptiform activity (spikes or sharp waves) seen in up to 2% of nl population; EEG w/in 24h, sleep deprivation and repeated studies ↑ dx yield of EEG.</p>
<p class="bl"><span class="sbl">•</span> Long-term EEG monitoring (hrs to days): if suspicion for non-convulsive status or non-epileptic seizures; video monitoring may help w/ nonepileptic seizures</p>
<p class="bl"><span class="sbl">•</span> MRI to r/o structural abnormalities; ↑ Se w/ fine coronal imaging of frontal &amp; temporal lobes</p>
<p class="bl"><span class="sbl">•</span> LP (if no space-occupying lesion on imaging): if suspect meningoencephalitis (eg, fever, ↑ WBC, nuchal rigidity) or autoimmune encephalitis and in <i class="calibre3">all</i> HIV ⊕ Pts</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Neurology</i> 2015;84:1705; <i class="calibre3">Lancet</i> 2015;385:884)</span></p>
<p class="bl"><span class="sbl">•</span> Treat any underlying precipitants, including CNS infections, intoxication, withdrawal, etc.</p>
<p class="bl"><span class="sbl">•</span> Antiepileptic drug (AED) Rx usually reserved for Pts w/ <span class="s">≥</span>2 <i class="calibre3">unprovoked</i> seizures, single seizure w/ high risk of recurrence (see below), or underlying structural abnormality. <i class="calibre3">Provoked</i> seizures generally treated by addressing underlying cause; consider AED if status epilepticus on presentation, focal neuro exam, postictal Todd’s paralysis.</p>
<p class="bl"><span class="sbl">•</span> After 1<sup class="calibre15">st</sup> unprovoked sz, weigh risks of recurrence vs AED. ↑ risk of recurrence if abnl EEG, MRI, or nocturnal sz. If EEG &amp; MRI nl → 65% sz-free at 5 y <span class="s1r">(<i class="calibre3">Lancet Neurol</i> 2006;5:317)</span>.</p>
<p class="bl"><span class="sbl">•</span> Immediate treatment w/ AED after 1<sup class="calibre15">st</sup> unprovoked seizure ↓ risk of recurrence over 2 y, but does not Δ long-term prognosis</p>
<p class="bl"><span class="sbl">•</span> If AED Rx indicated, choice dependent on type of seizure, side effects, cost, mechanism of elimination (if hepatic or renal insufficiency), teratogenesis, and drug interactions</p>
<p class="bl"><span class="sbl">•</span> Introduce gradually, monitor carefully</p>
<p class="bl"><span class="sbl">•</span> May consider withdrawal of meds if seizure free (typically for at least 1 y) and normal EEG</p>
<p class="bl"><span class="sbl">•</span> Individual state laws mandate seizure-free duration before being allowed to drive</p>
<p class="imagef"><img src="../images/00135.jpeg" alt="" class="calibre2"/></p>
<p class="fn">(<i class="calibre3">NEJM</i> 2008;359:166; <i class="calibre3">Lancet Neurol</i> 2011;10:446)</p>
<p class="h2a">Status epilepticus <span class="s">(<i class="calibre3">Epilepsy Curr</i> 2016;16:48)</span></p>
<p class="bl"><span class="sbl">•</span> ABCs: vital signs, oral airway or endotracheal intubation. Place Pt in semiprone position to ↓ risk of aspiration. Obtain IV access. Give thiamine, dextrose, IV normal saline.</p>
<p class="bl"><span class="sbl">•</span> STAT glc, metabolic panel, CBC, tox screen, lactate, AED levels, consider head CT, LP</p>
<p class="bl"><span class="sbl">•</span> Start standing AED after loading dose.</p>
<p class="imagef"><img src="../images/00136.jpeg" alt="" class="calibre2"/></p>
<p class="fn">PE, phenytoin equivalents. *Consider PR diazepam if no IV access and IM midazolam is contraindicated.</p>
<h2 class="ct"><a id="h113" class="calibre7"></a><a id="page_9-5" class="calibre7"></a><a href="part0002.html#rh125" class="calibre7">ALCOHOL WITHDRAWAL</a></h2>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Minor withdrawal sx (6–48 h after last drink): mild anxiety, tremulousness, HA</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Withdrawal seizures:</b> typically w/in 48 h after last drink; if unRx’d, 1/3 → delirium tremens</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Alcoholic hallucinosis:</b> isolated hallucinations (typically visual) 12–48 h after last drink</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Delirium tremens</b> (<b class="calibre4">DT</b>): disorientation, agitation, hallucinations, ↑ HR &amp; BP, fever, diaphoresis; begins 48–96 h after last drink, lasts 5–7 d</p>
<p class="bl"><span class="sbl">•</span> Consider other dx: CNS infxn or bleed, sz, drug O/D, coingestions, acute liver failure, GIB</p>
<p class="bl"><span class="sbl">•</span> Ten-item scale (CIWA-Ar) used to assess and manage alcohol withdrawal (see Appendix)</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">NEJM</i> 2003;348:1786)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Benzodiazepines</b> (BDZ)</p>
<p class="bl1">Drug: diazepam (long-acting w/ active metab; ↓ risk of recurrent withdrawal), lorazepam (short half-life), chlordiazepoxide, oxazepam (no active metab; good if cirrhosis)</p>
<p class="bl1">Dosing: typically start w/ diazepam 10–15 mg IV q10–15min (or lorazepam 2–4 mg IV q15–20min) until appropriate sedation achieved, then titrate to CIWA-Ar scale, evaluating q1h until score &lt;8 × 8 h, then q2h × 8 h, and if stable, then q4h <span class="s1r">(<i class="calibre3">JAMA</i> 1994;272:519)</span></p>
<p class="bl"><span class="sbl">•</span> If refractory to BDZ prn → BDZ gtt, phenobarb, dexmedetomidine, or propofol (&amp; intubation)</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Avoid</i> βB (mask sx)</p>
<p class="bl"><span class="sbl">•</span> Mechanical restraints as needed until chemical sedation achieved</p>
<p class="bl"><span class="sbl">•</span> Volume resuscitation as needed; thiamine <i class="calibre3">then</i> glc to prevent <i class="calibre3">Wernicke’s encephalopathy</i> (ataxia, ophthalmoplegia, short-term memory loss); replete K, Mg, PO<sub class="calibre8">4</sub></p>
<p class="bl"><span class="sbl">•</span> Prophylaxis: if min sx or asx (ie, CIWA score &lt;8) but prolonged heavy EtOH consumption or h/o withdrawal seizures or DTs → chlordiazepoxide 25–100 mg (based on severity of EtOH use) q6h × 24 h, then 25–50 mg q6h × 2 d</p>
<h2 class="ct"><a id="h114" class="calibre7"></a><a href="part0002.html#rh126" class="calibre7">DIZZINESS</a></h2>
<p class="h2a">Differential diagnosis</p>
<p class="bl"><span class="sbl">•</span> Includes a variety of sx. <b class="calibre4">Disequilibrium:</b> sense of imbalance, gait disturbance; <b class="calibre4">vertigo:</b> perception of spinning; <b class="calibre4">near syncope:</b> lightheadedness due to cerebral hypoperfusion.</p>
<p class="bl"><span class="sbl">•</span> Vertigo Ddx:</p>
<p class="bl1"><i class="calibre3">Peripheral</i></p>
<p class="bl2"><b class="calibre4">BPPV:</b> dislodged canaliths in semicircular canal; episodic rotatory vertigo (&lt;1 min episodes), triggered by changes in position; Rx: Epley/BBQ roll maneuver</p>
<p class="bl2"><b class="calibre4">Meniere’s disease:</b> ↑ endolymphatic pressure in inner ear; episodic rotatory vertigo (min-hrs), N/V, aural fullness, hearing loss, tinnitus; Rx: diuretics, ↓ salt</p>
<p class="bl2"><b class="calibre4">Vestibular neuritis:</b> sudden-onset w/ gait ataxia; if w/ hearing loss = labyrinthitis</p>
<p class="bl1"><i class="calibre3">Central</i></p>
<p class="bl2"><b class="calibre4">Posterior circulation stroke/TIA:</b> “5 Ds” of dizziness, diplopia, dysarthria, dysphagia, dystaxia; sudden onset (resolves after mins in TIA, persists in stroke)</p>
<p class="bl2"><b class="calibre4">Other:</b> migraine, Chiari, epilepsy, MS, tumors, drugs/meds, concussion</p>
<p class="h2a">Initial evaluation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hx:</b> ask open-ended questions (description by Pt may be unreliable), pace of illness, episodic vs. chronic, meds, other sx of posterior circ including diplopia, dysarthria, ataxia</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre70"/>
<col class="calibre71"/>
<col class="calibre71"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead">Exam</p></td>
<td class="bg1-b"><p class="tabhead">Peripheral Causes</p></td>
<td class="bg1-b"><p class="tabhead">Central Causes</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Orthostatics</p></td>
<td class="bg0-br"><p class="tab">⊕ in orthostatic syncope</p></td>
<td class="bg0-b"><p class="tab">Typically absent</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Eye movements</p></td>
<td class="bg0-br"><p class="tab">Nystagmus unidirectional if present, never vertical, suppressed w/ fixation</p></td>
<td class="bg0-b"><p class="tab">Nystagmus bidirectional, often vertical, not suppressed w/ fixation</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Hearing</p></td>
<td class="bg0-br"><p class="tab">May be impaired in some peripheral causes of vertigo</p></td>
<td class="bg0-b"><p class="tab">Normal (rarely unilat. hearing loss in AICA-territory stroke)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Coord./gait</p></td>
<td class="bg0-r"><p class="tab">Normal</p></td>
<td class="bg"><p class="tab">May reveal limb, trunk, gait ataxia</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HINTS testing</b> <span class="s1r">(<i class="calibre3">Stroke</i> 2009;40:3504)</span></p>
<p class="bl1">Head impulse test: Pt fixates on examiner’s nose during rapid passive head turn; presence of “catch-up saccade” supports peripheral dysfunction to side of turn</p>
<p class="bl1">Nystagmus (see table above)</p>
<p class="bl1">Test of skew: vertical refixation saccade on alternating eye cover supports central cause</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dix-Hallpike test:</b> Pt sitting → lying back w/ 45º head tilt; elicits rotatory nystagmus after delay of secs; fatigues if repeated; ⊕ suggests BPPV w/ affected ear down</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Supine Roll test:</b> nystagmus elicited by head turn while patient supine; when ⊕ suggests BPPV w/ affected ear down (lateral canal, 8% of cases)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Studies:</b> ECG, basic labs, if concerning s/s on HINTS → MRI brain</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Treatment:</b> reposition maneuv. for BPPV, vestib. PT; anti-hist., sedatives or anti-emetics</p>
<h2 class="ct"><a id="h115" class="calibre7"></a><a id="page_9-6" class="calibre7"></a><a href="part0002.html#rh127" class="calibre7">STROKE</a></h2>
<p class="h">I<small class="calibre30">SCHEMIC</small> S<small class="calibre30">TROKE</small></p>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> Embolic: artery → artery, cardioembolic (~30% due to AF; <i class="calibre3">NEJM</i> 2014;370:2478), paradoxical</p>
<p class="bl"><span class="sbl">•</span> Thrombotic: large vessel (atherosclerosis) vs. small vessel (“lacunar,” lipohyalinosis of small arteries, often related to smoking, HTN, hyperlipidemia, &amp; DM)</p>
<p class="bl"><span class="sbl">•</span> Other: dissection, vasculitis, vasospasm, hypercoag, hypoperfusion, endocarditis, venous</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Timing: embolic → sudden onset; thrombotic → may have stuttering course</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre10"/>
<col class="calibre11"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc">Stroke Syndromes by Vascular Territory</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabheadc">Artery</p></td>
<td class="bg0-b"><p class="tabhead">Deficits</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">ICA → Ophth</p></td>
<td class="bg0-b"><p class="tab">Amaurosis fugax (transient monocular blindness)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">ACA</p></td>
<td class="bg0-b"><p class="tab">Hemiplegia (leg &gt; arm), abulia, urinary incontinence, primitive reflexes</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">MCA</p></td>
<td class="bg0-b"><p class="tab">Hemiplegia (face &amp; arm &gt; leg); hemianesthesia; homonymous hemianopia</p>
<p class="tab">Aphasia if dom. hemisphere: sup. div. → expressive; inf. div → receptive</p>
<p class="tab">Apraxia &amp; neglect if nondom. hemisphere.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">PCA</p></td>
<td class="bg0-b"><p class="tab">Macular-sparing homonymous hemianopia; alexia w/o agraphia</p>
<p class="tab">Thalamic syndromes with contralateral hemisensory disturbance</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Vertebral, PICA</p></td>
<td class="bg0-b"><p class="tab">Wallenberg syndrome = numbness of ipsilateral face and contralateral limbs, diplopia, dysarthria, dysphagia, ipsilateral Horner’s, hiccups</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Basilar</p></td>
<td class="bg0-b"><p class="tab">Pupillary Δs (midbrain=dilated, pons=pinpoint), long tract signs (quadriplegia, sensory loss), CN abnl, cerebellar dysfxn. Top of basilar → “locked in” synd.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Cerebellar</p></td>
<td class="bg0-b"><p class="tab">Vertigo, N/V, diplopia, dysarthria, nystagmus, ipsilateral limb ataxia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc">Lacunar (arterioles)</p></td>
<td class="bg"><p class="tab">5 major syndromes: pure hemiplegia, pure hemianesthesia, ataxic hemiparesis, dysarthria + clumsy hand, mixed sensorimotor</p></td>
</tr>
</table>
<p class="h2a">Transient ischemic attack (TIA)</p>
<p class="bl"><span class="sbl">•</span> Sudden deficit due to cerebral ischemia; <b class="calibre4">no stroke on imaging;</b> most resolve in &lt;1 h</p>
<p class="bl"><span class="sbl">•</span> Ddx: seizure, migraine, hypoglycemia, amyloid spells, TGA, anxiety</p>
<p class="bl"><span class="sbl">•</span> Risk of subsequent stroke ~2% by 1 wk <span class="s1r">(<i class="calibre3">NEJM</i> 2016;374:1533)</span>. Can stratify based on <b class="calibre4">ABCD<sup class="calibre15">2</sup>: A</b>ge <span class="s">≥</span>60 y (+1); <b class="calibre4">B</b>P <span class="s">≥</span>140/90 (+1); <b class="calibre4">C</b>lin features: unilat. weak. (+2), speech impair. w/o weakness (+1); <b class="calibre4">D</b>uration <span class="s">≥</span>60 (+2) or 10–59 min (+1); <b class="calibre4">D</b>M (+1)</p>
<p class="h2a">Physical exam</p>
<p class="bl"><span class="sbl">•</span> General: murmurs, carotid &amp; subclavian bruits, peripheral emboli, endocarditis stigmata</p>
<p class="bl"><span class="sbl">•</span> Neurologic exam, NIH stroke scale (<a href="http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf" class="calibre1">http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf</a>)</p>
<p class="h2a">Acute workup</p>
<p class="bl"><span class="sbl">•</span> Electrolytes, Cr (relevant for contrast); glc, CBC, coags (see exclusion criteria for lysis)</p>
<p class="bl"><span class="sbl">•</span> Cardiac biomarkers, 12-lead ECG, tox screen</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">STAT CT</b> to r/o ICH prior to lysis. (Se ICH ≈ MRI, CT faster). Early signs of stroke: hyperdense artery, loss of gray-white differentiation, edema, insular ribbon. CT can be nl initially, and not Se for small &amp; brainstem. CTA if considering endovascular intervention.</p>
<p class="h2a">Acute treatment of ischemic stroke <span class="s">(<i class="calibre3">Lancet</i> 2017;389:641; <i class="calibre3">Stroke</i> 2018;49:e46)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Thrombolysis (IV):</b> tPA 0.9 mg/kg (max 90 mg), w/ 10% as bolus over 1 min, rest over 1 h</p>
<p class="bl1">consider if onset w/in 4.5 h, ∅ ICH, ∅ contraindic. (incl. current/prior ICH; head trauma or stroke w/in 3 mo; intracranial neoplasm, AVM or aneurysm; recent intracranial/intraspinal surgery; active internal bleeding; noncompressible arterial puncture; ↑ BP; multilobar infarct; plt &lt;100k, INR &gt;1.7, on Xa inhib, PTT &gt;40, glc &lt;50)</p>
<p class="bl1">0–3 h: 12% absolute ↑ in good neuro outcome (min/no disability), 5.8% absolute ↑ in ICH, trend toward 4% absolute ↓ mortality</p>
<p class="bl1">3–4.5 h: 7.4% absolute ↑ in good neuro outcome, 1.8% absolute ↑ in ICH, ∅ mortality benefit (nb, trial excluded patients with previous strokes + DM)</p>
<p class="bl1">Data for TNK, Rx up to 9 h, and for MRI imaging to guide Rx <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:1573 &amp; 379:611; 2019;380:1795)</span></p>
<p class="bl"><span class="sbl">•</span> BP: lower to &lt;185/110 to consider lysis; if lyse keep &lt;180/105 × 24 h (consider labetalol or nicardipine), o/w permissive HTN unless &gt;220/120 or sx; if sx HoTN consider vasopressors</p>
<p class="bl"><span class="sbl">•</span> Initiate ASA w/in 24–48 h; avoid anticoagulation w/in 24 h of lysis; see below for long-term Rx</p>
<p class="bl"><span class="sbl">•</span> Cerebral edema → herniation: 1–5 d post large MCA or cerebellar strokes, ↑ risk in young. Elevate HOB &gt;30°; mannitol ± 23% NaCl. Hemicraniectomy ↓ mortality <span class="s1r">(<i class="calibre3">NEJM</i> 2014;370:1091)</span>. Neurosurgery consult in select MCA and all large cerebellar strokes.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Endovascular thrombectomy</b> indicated if w/in 6 h of sx onset, pre mRS 0-1, occlusion in ICA or MCA, NIHSS ≥6 (clinical severity), ASPECTS ≥6 (CT based likelihood of recovery) <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:11, 1009, 1019, 2285 &amp; 2296; <i class="calibre3">Lancet</i> 2016;387:1723)</span>. May extend to 6–24 h if mismatch between infarct size and clinical deficits or stroke penumbra <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:11 &amp; 708)</span>.</p>
<p class="h2a"><a id="page_9-7" class="calibre1"></a><b class="calibre4">Workup to assess for etiology/modifiable risk factors</b></p>
<p class="bl"><span class="sbl">•</span> Cardiac: prolonged Holter for AF (eg, 10 d at presentation, 3 &amp; 6 mo detects in 14%); TTE to r/o thrombus/veg, w/ bubble study to r/o PFO/atrial septal aneurysm if suspect embolic</p>
<p class="bl"><span class="sbl">•</span> Vessel imaging: CTA or MRA head/neck; carotid U/S w/ Doppler if contraindic to CTA/MRA</p>
<p class="bl"><span class="sbl">•</span> Labs: lipids, HbA1c, TSH, homocysteine, Lp(a), hypercoag w/u (if &lt;65 y or cryptogenic stroke; ideally drawn before starting anticoag), ESR/CRP, blood cx if s/s systemic infection</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">MRI</b> helpful if dx of stroke unclear (esp. post circ) or to define stroke subtype, age, exact size</p>
<p class="bl1"><i class="calibre3">DWI</i> bright/<i class="calibre3">ADC</i> dark = earliest finding in acute ischemia (~w/in mins, up to days)</p>
<p class="bl1"><i class="calibre3">T2-FLAIR:</i> hyperintense w/in hrs, persists for wks; <i class="calibre3">PWI</i> differentiates irreversibly infarcted core vs. viable penumbra; <i class="calibre3">T1 fat-sat</i> (neck vessels) if suspicious for dissection</p>
<p class="h2a">Secondary stroke prevention <span class="s">(<i class="calibre3">NEJM</i> 2012;366:1914)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Antiplatelet therapy:</b> different agents likely have similar efficacy</p>
<p class="bl1"><b class="calibre4">ASA</b> ↓ death &amp; repeat stroke; equal to warfarin in nonembolic stroke <span class="s1r">(<i class="calibre3">NEJM</i> 2001;345:1444)</span></p>
<p class="bl1"><b class="calibre4">clopidogrel:</b> marginally superior to ASA, slightly ↑ ICH <span class="s1r">(<i class="calibre3">Lancet</i> 1996;348:1329)</span></p>
<p class="bl1"><b class="calibre4">clopidogrel + ASA</b> (vs. ASA alone): Rx for 21 d in minor strokes/TIA → ↓ risk of stroke, ? ↑ ICH; longer Rx not better &amp; ↑ ICH <span class="s1r">(<i class="calibre3">NEJM</i> 2013;369:11 &amp; 2018;379:215; <i class="calibre3">BMJ</i> 2018;363:k5108)</span> Rx for 90 d if stroke due to intracranial athero <span class="s1r">(<i class="calibre3">NEJM</i> 2011;365:993)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Anticoagulation (AC):</b> consider for AF (qv), cardiac/paradoxical emboli (except bacterial endocard); large extra-dural dissections; hypercoag; bridge to CEA in sx carotid stenosis</p>
<p class="bl1"><b class="calibre4">Hold off on AC</b> in large strokes for ~2–4 wk given risk of hemorrhagic conversion</p>
<p class="bl"><span class="sbl">•</span> Long-term SBP target 120–139 mmHg <span class="s1r">(<i class="calibre3">JAMA</i> 2011;306:2137)</span></p>
<p class="bl"><span class="sbl">•</span> ↓ LDL-C (&lt;&lt; 70 mg/dL): ↓ recurrence w/ statin PCSk9i added to statin <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:1713)</span></p>
<p class="bl"><span class="sbl">•</span> Fluoxetine: improved motor recovery after 3 mo <span class="s1r">(<i class="calibre3">Lancet Neurol</i> 2011;10:123)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Carotid revascularization</b> <span class="s1r">(<i class="calibre3">NEJM</i> 2013;369:1143)</span></p>
<p class="bl1"><b class="calibre4">CEA</b> <span class="s1r">(<i class="calibre3">if</i> surgical morbidity &amp; mortality <span class="s3">≤</span>6%)</span> indicated for:</p>
<p class="bl2"><i class="calibre3">sx stenosis</i> 70–99% (benefit ↑ for males, &gt;75 y, <span class="s">≤</span>2 wk from stroke) → 65% ↓ RR of repeat stroke, slight benefit for 50–69% stenosis <span class="s">(<i class="calibre3">NEJM</i> 1991;325:445; <i class="calibre3">Lancet</i> 2004;363:915)</span></p>
<p class="bl2"><i class="calibre3">asx stenosis</i> 70–90%, &lt;79 y: 50% ↓ RR of repeat stroke <span class="s1r">(<i class="calibre3">Lancet</i> 2010;376:1074)</span></p>
<p class="bl1"><b class="calibre4">Stenting:</b> c/w CEA, periprocedural stroke ↑ (esp. in elderly) &amp; MI ↓ (but many asx), subseq. stroke rate ≈ <span class="s1r">(<i class="calibre3">NEJM</i> 2016;374:1011 &amp; 1021; <i class="calibre3">Lancet</i> 2016;387:1305; <i class="calibre3">Lancet Neuro</i> 2019;18:348)</span></p>
<p class="h2a">Patent foramen ovale <span class="s">(PFO; in ~27% of population) <span class="tfont1">(<i class="calibre3">NEJM</i> 2005;353:2361)</span></span></p>
<p class="bl"><span class="sbl">•</span> ↑ stroke risk: <span class="s">≥</span>4 mm separation, R→L shunting at rest, ↑ septal mobility, atrial septal aneurysm</p>
<p class="bl"><span class="sbl">•</span> If PFO &amp; stroke/TIA: no benefit of warfarin over ASA <span class="s1r">(<i class="calibre3">Circ</i> 2002;105:2625)</span>, but consider if at high risk for or has DVT/PE. Closure ↓ recurrence by ≥50% if ↑ risk features (see above) and absence of factors suggesting alternate etiology <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:1011, 1022, 1033)</span>. <b class="calibre4">RoPE score:</b> age (+1 for each decade &lt;70); cortical stroke on imaging (+1); HTN, DM, h/o stroke/TIA, smoker (+1 for each <i class="calibre3">absent</i> risk factor). Consider closure if &gt;7 <span class="s1r">(<i class="calibre3">JAHA</i> 2018;7:1)</span>.</p>
<p class="h">I<small class="calibre30">NTRACRANIAL</small> H<small class="calibre30">EMORRHAGE</small> (ICH)</p>
<p class="h2a">Classification by location</p>
<p class="bl"><span class="sbl">•</span> Hemorrhagic strokes: intraparenchymal hemorrhage (IPH) &amp; subarachnoid hemorrhage (SAH)</p>
<p class="bl"><span class="sbl">•</span> Other ICH: epidural hematoma (EDH) &amp; subdural hematoma (SDH)</p>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> AVM, aneurysm, cerebral venous sinus thrombosis → IPH or SAH</p>
<p class="bl"><span class="sbl">•</span> HTN (basal ganglia, cerebellum, brainstem), cerebral amyloid (lobar), tumor (esp. w/ melanoma, renal cell CA, chorio-CA, thyroid CA) → IPH</p>
<p class="bl"><span class="sbl">•</span> Trauma → all locations (nb, IPH or SAH caused by trauma technically not a stroke)</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Lancet</i> 2017;389:655 &amp; <i class="calibre3">NEJM</i> 2017;377:257)</span></p>
<p class="bl"><span class="sbl">•</span> ↓ consciousness, N/V, HA, progressive focal neurologic deficits</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">SAH:</i> thunderclap HA, onset w/ exertion; nuchal pain/rigidity; LOC. <i class="calibre3">EDH:</i> initial lucid interval.</p>
<p class="h2a">Workup <span class="s">(<i class="calibre3">Acad Emerg Med</i> 2016;23:963)</span></p>
<p class="bl"><span class="sbl">•</span> STAT CT brain, angio (CT-A or conventional) if suspicious for vascular source</p>
<p class="bl"><span class="sbl">•</span> ? LP for xanthochromia if no evid of ICH on CT (although ⊖ LR 0.01) &amp; suspicious for SAH</p>
<p class="bl"><span class="sbl">•</span> Coags (PT, PTT, INR)</p>
<p class="h2a">Management <span class="s">(<i class="calibre3">Crit Care Med</i> 2016;44:2251; <i class="calibre3">JAMA</i> 2019;321:1295)</span></p>
<p class="bl"><span class="sbl">•</span> Reverse coagulopathy, INR &lt;1.4. Plt &gt;100k, no need for plt tx if on antiplt Rx (? if ↑ ICH), DDAVP if uremic. 2-3 mo after recovers, can restart antiplt mono Rx <span class="s1r">(<i class="calibre3">Lancet</i> 2019;393:2013)</span>.</p>
<p class="bl"><span class="sbl">•</span> BP control w/ art line, nicardipine or labetalol gtt. SBP goal &lt;140 for 1<sup class="calibre15">st</sup> 24 h, then &lt;160 <span class="s1r">(<i class="calibre3">NEJM</i> 2013;368:2355 &amp; 2016;375:1033)</span>, though BP goals controversial <span class="s1r">(<i class="calibre3">NEJM</i> 2016;375:1033)</span></p>
<p class="bl"><span class="sbl">•</span> SAH: endovasc coiling vs. surg clipping (depends on location, comorbid.; <i class="calibre3">Lancet</i> 2015;385:691) of aneurysm/AVM; nimodipine to ↓ risk of vasospasm (monitor w/ TCDs), seizure Ppx</p>
<p class="bl"><span class="sbl">•</span> Surg evac: EDH; SDH if &gt;1 cm or rapid ↑; IPH: no obvious benefit <span class="s1r">(<i class="calibre3">Lancet</i> 2013;382:397)</span></p>
<p class="bl"><span class="sbl">•</span> Venous sinus thrombosis: start anticoagulation, manage ↑ ICP and seizures as needed</p>
<h2 class="ct"><a id="h116" class="calibre7"></a><a id="page_9-8" class="calibre7"></a><a href="part0002.html#rh128" class="calibre7">WEAKNESS &amp; NEUROMUSCULAR DYSFUNCTION</a></h2>
<p class="image1"><img src="../images/00137.jpeg" alt="" class="calibre2"/></p>
<p class="h">P<small class="calibre30">ERIPHERAL</small> N<small class="calibre30">EUROPATHIES</small></p>
<p class="h2a">Etiologies based on presentation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mononeuropathy</b> (1 nerve): <i class="calibre3">acute</i> → trauma; <i class="calibre3">chronic</i> → entrapment, compression, DM, Lyme. Common: median n. (carpal tunnel); ulnar n. (elbow or wrist); radial n. (spiral groove); com. peroneal n. (fibular head w/ leg crossing); lat. femoral cutan. n. (inguinal lig)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mononeuropathy multiplex</b> (axonal loss of multiple, noncontig. nerves): vasculitic synd. (eg, PAN, Churg–Strauss, Wegener’s, SLE, RA, Sjögren’s, cryo, HCV), DM, Lyme, HIV, leprosy, hereditary neurop. w/ pressure palsies, infiltrative (sarcoid, lymphoma, leukemia)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Polyneuropathy</b> (multiple symmetric nerves, generally length dependent): 30% idiopathic;</p>
<p class="bl1"><i class="calibre3">W/ autonomic features:</i> DM, EtOH, paraneoplastic, B<sub class="calibre8">12</sub> def, amyloid, chemo, 1° dysauto</p>
<p class="bl1"><i class="calibre3">Painful (small fiber nerves):</i> DM, EtOH, amyloid, chemo, sarcoid, heavy metals, porphyria</p>
<p class="bl1"><i class="calibre3">Demyelinating.</i> <span class="underline">Acute</span>: AIDP (Guillain-Barré), diphtheria. <span class="underline">Subacute</span>: meds (taxanes), paraneoplastic. <span class="underline">Chronic</span>: idiopathic, DM, CIDP, anti-MAG, HIV, hypothyroidism, toxins, paraproteinemia, hereditary (eg, CMT).</p>
<p class="bl1"><i class="calibre3">Axonal.</i> <span class="underline">Acute</span>: acute motor axonal neuropathy, porphyria, vasculitis, uremia, critical illness. <span class="underline">Subacute</span>: EtOH, sepsis, paraneoplastic, meds (cisplatin, paclitaxel, vincristine, INH, ddI, amio). <span class="underline">Chronic</span>: DM, uremia, lead, arsenic, HIV, paraproteinemia, B<sub class="calibre8">12</sub> defic.</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Weakness, fasciculations, cramps, numbness, dysesthesias (burning/tingling), allodynia</p>
<p class="bl"><span class="sbl">•</span> ± Autonomic dysfxn (orthostasis, constipation, urinary retention, impotence, abnl sweating)</p>
<p class="bl"><span class="sbl">•</span> Depressed or absent DTRs (may be normal in small fiber neuropathy)</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Distal symmetric polyneuropathy: CBC, lytes, BUN/Cr, Hb<sub class="calibre8">A1C</sub>, B<sub class="calibre8">12</sub>, TSH, ESR, SPEP + IF</p>
<p class="bl"><span class="sbl">•</span> EMG/NCS (often no change in 1<sup class="calibre15">st</sup> 10–14 d or in small-fiber neuropathy)</p>
<p class="bl"><span class="sbl">•</span> Based on H&amp;P: LFTs, ANA, anti-Ro/La, HIV, Cu, Lyme, RPR, UA, UPEP+IF, ACE, ANCA, heavy metals, LP (AIDP/CIDP), cryo, paraneoplastic Abs, genetic testing. Autonomic testing/skin bx (small fiber), nerve bx (mononeuropathy multiplex), fat pad bx (amyloid).</p>
<p class="bl"><span class="sbl">•</span> MRI if possible radiculopathy or plexopathy (after EMG)</p>
<p class="h2a">Pharmacologic treatment of neuropathic pain <span class="s">(<i class="calibre3">Lancet Neurol</i> 2015;14:162)</span></p>
<p class="bl"><span class="sbl">•</span> Gabapentin, pregabalin, TCAs (nortriptyline, amitriptyline), SNRIs (duloxetine, venlafaxine)</p>
<p class="bl"><span class="sbl">•</span> 2<sup class="calibre15">nd</sup> line: tramadol, topicals (lido, capsaicin); 3<sup class="calibre15">rd</sup> line: nerve block, botulinum toxin A</p>
<p class="h">G<small class="calibre30">UILLAIN</small>-B<small class="calibre30">ARRÉ</small> S<small class="calibre30">YNDROME</small> (GBS)</p>
<p class="h2a">Definition &amp; epidemiology <span class="s">(<i class="calibre3">Nat Rev Neurol</i> 2014;10:469)</span></p>
<p class="bl"><span class="sbl">•</span> AIDP (60–80%); acute motor axonal neuropathy (AMAN; 7–30%; a/w anti-GM1, anti-GD1a Abs; worse prognosis); Miller Fisher synd. (ophthalmoplegia &amp; ataxia; a/w anti-GQ1b Ab)</p>
<p class="bl"><span class="sbl">•</span> Incidence 1–2 per 100,000; most common acute/subacute paralysis</p>
<p class="bl"><span class="sbl">•</span> Precipitants in 60%: viral illness (influenza, CMV, EBV, HIV, Zika), URI (<i class="calibre3">Mycoplasma</i>), gastroenteritis (<i class="calibre3">Campylobacter</i>), Lyme, immunizations (no proven risk w/ current), surgery</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Lancet</i> 2016;388:717)</span></p>
<p class="bl"><span class="sbl">•</span> Pain (55–90%), distal sensory dysesthesias &amp; numbness often 1<sup class="calibre15">st</sup> sx, back pain common</p>
<p class="bl"><span class="sbl">•</span> Progressive symmetric paralysis in legs and arms over hrs to days; plateau in 1–4 wk</p>
<p class="bl"><span class="sbl">•</span> Hypoactive then absent reflexes. &lt;10% w/ reflexes on presentation, but all develop hypo/areflexia during course. Minority of AMAN w/ preserved reflexes throughout.</p>
<p class="bl"><span class="sbl">•</span> Resp failure requiring mech vent occurs in 25%; autonomic instability &amp; arrhythmias in 60%</p>
<p class="h2a">Diagnostic studies <span class="s">(results may be normal in first several days)</span></p>
<p class="bl"><span class="sbl">•</span> LP: albuminocytologic dissociation = ↑ protein w/o pleocytosis (&lt;10 WBCs) seen in up to 64% of Pts. ↑ protein in ½ in 1<sup class="calibre15">st</sup> wk, ¾ by 3<sup class="calibre15">rd</sup> wk of sx. Unlikely to be GBS if WBC &gt;50</p>
<p class="bl"><span class="sbl">•</span> EMG/NCS: ↓ conduction velocity, conduction block, abnl F-waves; can be nl in 1<sup class="calibre15">st</sup> 2 wk</p>
<p class="bl"><span class="sbl">•</span> FVC &amp; NIF: to assess for risk of resp. failure (cannot rely on P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> or S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> alone)</p>
<p class="h2a"><a id="page_9-9" class="calibre1"></a><b class="calibre4">Treatment</b></p>
<p class="bl"><span class="sbl">•</span> Plasma exchange or IVIg of equal efficacy <span class="s1r">(<i class="calibre3">Neuro</i> 2012;78:1009)</span>; steroids not beneficial</p>
<p class="bl"><span class="sbl">•</span> Supportive care with monitoring in ICU setting if rapid progression or resp. failure</p>
<p class="bl"><span class="sbl">•</span> Watch for autonomic dysfunction: labile BP, dysrhythmias (telemetry)</p>
<p class="bl"><span class="sbl">•</span> Erasmus GBS outcome score can help w/ prognostication <span class="s1r">(<i class="calibre3">Lancet Neurol</i> 2007;6:589)</span>. Most recover near baseline in 1 y; 3–5% mortality. Residual deficits: pain, fatigue.</p>
<p class="h">M<small class="calibre30">YASTHENIA</small> G<small class="calibre30">RAVIS</small> (MG)</p>
<p class="h2a">Definition &amp; epidemiology <span class="s">(<i class="calibre3">Lancet Neurol</i> 2015;14:1023; <i class="calibre3">NEJM</i> 2016;375:2570)</span></p>
<p class="bl"><span class="sbl">•</span> Autoimmune disorder with Ab against acetylcholine receptor (AChR, 80%), muscle-specific kinase (MusK, 4%), lipoprotein-related protein 4 (LRP4, 2%), or other NMJ proteins</p>
<p class="bl"><span class="sbl">•</span> Prevalence: 1 in 7500; affects all ages, peak incidence 20s–30s (women), 60s–70s (men)</p>
<p class="bl"><span class="sbl">•</span> 15% of AchR MG a/w thymoma; 30% of pts w/ thymoma develop AchR MG</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Fluctuating weakness w/ <i class="calibre3">fatigability</i> (worse w/ repetitive use, relieved by rest)</p>
<p class="bl"><span class="sbl">•</span> Cranial muscles involved early → 60% present initially w/ ocular sx (ptosis, diplopia); 20% will only have ocular sx; 15% w/ bulbar (difficulty chewing, dysarthria, dysphagia)</p>
<p class="bl"><span class="sbl">•</span> Limb weakness proximal &gt; distal; DTRs preserved; minimal/no atrophy</p>
<p class="bl"><span class="sbl">•</span> MusK MG (F &gt;&gt; M): mostly cranial/bulbar, neck, and resp weakness</p>
<p class="bl"><span class="sbl">•</span> Exacerb. triggered by stressors: URI, surgery, preg/postpartum, meds (eg, Mg, AG, macro-lides, FQ, procainamide, phenytoin, D-penicillamine). Prednisone can <i class="calibre3">worsen</i> sx acutely.</p>
<p class="bl"><span class="sbl">•</span> Myasthenic crisis = sx exacerbation, risk of respiratory compromise</p>
<p class="bl"><span class="sbl">•</span> Cholinergic crisis = weakness due to <i class="calibre3">overtreatment</i> with anticholinesterase meds; may have excessive salivation, abdominal cramping and diarrhea; rare at normal doses</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Bedside: ptosis at baseline or after &gt;45 sec of sustained upgaze; improved ptosis with ice pack over eyes for 2–5 min (Se 77%, Sp 98%)</p>
<p class="bl"><span class="sbl">•</span> Neostigmine test: temporary ↑ strength; false ⊕ &amp; ⊖ occur; premedicate w/ atropine</p>
<p class="bl"><span class="sbl">•</span> EMG: ↓ response with repetitive nerve stimulation (vs. ↑ response in Lambert-Eaton)</p>
<p class="bl"><span class="sbl">•</span> Anti-AChR Ab (Se 80%, 50% if ocular disease only, Sp &gt;90%); muscle specific receptor tyrosine kinase (MuSK) Ab; AchR modulating Ab</p>
<p class="bl"><span class="sbl">•</span> CT or MRI of thorax to evaluate thymus (65% hyperplasia, 10% thymoma)</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Thymectomy if thymoma and in Ab ⊕ Pts w/o thymoma <span class="s1r">(<i class="calibre3">NEJM</i> 2016;375:511)</span></p>
<p class="bl"><span class="sbl">•</span> Cholinesterase inhibitor (eg, pyridostigmine) is most rapid acting (benefit in 30–60 min). Less effective for MusK MG. Side effects: cholinergic stim (brady, diarrhea, drooling).</p>
<p class="bl"><span class="sbl">•</span> Immunosuppression: prednisone (benefit in wks; don’t start during crisis) + AZA (benefit in 6–15 mo). If no response: mycophenolate, rituximab, MTZ, CsA. Goal to taper off steroids</p>
<p class="bl"><span class="sbl">•</span> Myasthenic crisis: treat precipitant; consider d/c cholinesterase inhibitor if suspect cholinergic crisis. IVIg or plasmapheresis; if no response, high-dose glucocorticoids (in monitored setting b/c risk for initial worsening). ICU if rapid or severe (follow FVC, NIF).</p>
<p class="h">M<small class="calibre30">YOPATHIES</small></p>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> Hereditary: Duchenne, Becker, limb-girdle, myotonic, metabolic, mitochondrial</p>
<p class="bl"><span class="sbl">•</span> Endocrine: hypothyroidism, hyperparathyroidism, Cushing syndrome</p>
<p class="bl"><span class="sbl">•</span> Toxic: statins, fibrates, glucocorticoids, zidovudine, alcohol, cocaine, antimalarials, colchicine, penicillamine</p>
<p class="bl"><span class="sbl">•</span> Infectious: HIV, HTLV-1, trichinosis, toxoplasmosis</p>
<p class="bl"><span class="sbl">•</span> Inflammatory: polymyositis, dermatomyositis, inclusion body myositis, anti-HMGCR</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Progressive or episodic weakness (not fatigue)</p>
<p class="bl"><span class="sbl">•</span> Weakness most often symmetric, proximal &gt; distal (stairs, rising from sitting, etc.)</p>
<p class="bl"><span class="sbl">•</span> ± Myalgias (though not prominent or frequent), cramps, myotonia (impaired relaxation)</p>
<p class="bl"><span class="sbl">•</span> May develop either pseudohypertrophy (dystrophies) or mild muscle atrophy</p>
<p class="bl"><span class="sbl">•</span> Assoc. organ dysfxn: cardiac (arrhythmia, CHF), pulmonary (ILD), dysmorphic features</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> CK, aldolase, LDH, electrolytes, ALT/AST, PTH, TSH, ESR, HIV</p>
<p class="bl"><span class="sbl">•</span> Autoantibodies: ANA, RF, anti-Jo1, antisynthetase, anti-Mi-2, anti-SRP, anti-HMGCR (if statin use), 5TN1CA (in inclusion body myositis)</p>
<p class="bl"><span class="sbl">•</span> EMG/NCS: low-amplitude, polyphasic units w/ early recruitment, ± fibrillation potentials</p>
<p class="bl"><span class="sbl">•</span> Muscle biopsy, molecular genetic testing (where indicated)</p>
<p class="bl"><span class="sbl">•</span> Age-appropriate cancer screening if polymyositis or dermatomyositis suspected</p>
<h2 class="ct"><a id="h117" class="calibre7"></a><a id="page_9-10" class="calibre7"></a><a href="part0002.html#rh129" class="calibre7">HEADACHE</a></h2>
<p class="h2a"><b class="calibre4">Primary headache syndromes</b> <span class="s">(International Headache Society Classification)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Tension-type:</b> bilateral, pressure-like pain of mild–mod intensity, not throbbing or aggra-vated by physical activity. A/w photophobia or phonophobia, not N/V. Freq a/w myofascial sensitivity in neck/head. Triggers: stress, sleep deprivation, dehydration, hunger. Episodic HA Rx: NSAIDs, acetaminophen (risk of med overuse HA); chronic HA Rx: TCAs.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cluster HA</b> and other trigeminal autonomic cephalalgias (TACs) <span class="s1r">(<i class="calibre3">Continuum</i> 2018;24:1137)</span></p>
<p class="bl1">Characterized by unilateral headache a/w ipsilateral autonomic sx (rhinorrhea, red/tearing eye, miosis, ptosis, lid edema, sweating), subtypes differentiated by timing.</p>
<p class="bl1"><i class="calibre3">Cluster:</i> ♂ &gt; ♀, unilateral pain w/ autonomic sx &amp; restlessness; attacks 15 min–3 h, up to 8/d (circadian). Ppx: CCB (verapamil). Rx: high-flow O<sub class="calibre8">2</sub> (12–15 L/min), sumatriptan.</p>
<p class="bl1"><i class="calibre3">Paroxysmal hemicrania:</i> similar to cluster, but ♀ &gt; ♂, attacks 2–30 min. Rx: indomethacin.</p>
<p class="bl1"><i class="calibre3">Hemicrania continua:</i> ♀ &gt; ♂, ice pick–like pain lasting &gt;3 mo. Rx: indomethacin.</p>
<p class="bl1"><i class="calibre3">Short-lasting unilateral neuralgiform HA</i> (SUNA/SUNCT)<i class="calibre3">:</i> ♂ &gt; ♀, excruciating, stabbing, electrical pain, 5 sec–4 min, up to 200×/d. Rx: lamotrigine, gabapentin, topiramate.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Migraine:</b> <i class="calibre3">see below</i></p>
<p class="h2a">Secondary causes of headaches</p>
<p class="bl"><span class="sbl">•</span> Traumatic: post-concussion, SAH, SDH, postcraniotomy</p>
<p class="bl"><span class="sbl">•</span> ↑ ICP: mass (tumor, abscess, vascular malformations, ICH), hydrocephalus, idiopathic intracranial hypertension (pseudotumor cerebri), altitude-associated cerebral edema</p>
<p class="bl"><span class="sbl">•</span> ↓ ICP: post-LP headache, CSF leak/dural tear, overshunting</p>
<p class="bl"><span class="sbl">•</span> Vascular: stroke (esp. posterior circ), dissection, vasculitis (incl. temporal arteritis), reversible cerebral vasoconstriction syndrome (RCVS), ICH, venous sinus thrombosis</p>
<p class="bl"><span class="sbl">•</span> Meningeal irritation: meningitis, SAH</p>
<p class="bl"><span class="sbl">•</span> Extracranial: sinusitis, TMJ syndrome, glaucoma</p>
<p class="bl"><span class="sbl">•</span> Systemic: hypoxia (OSA), hypercapnia, dialysis, HTN, cardiac cephalalgia, hypoglycemia, ↓ TSH, pheo, medication overuse (analgesics), withdrawal (caffeine, opioids, estrogen)</p>
<p class="h2a">Clinical evaluation <span class="s">(<i class="calibre3">JAMA</i> 2006;296:1274 &amp; 2013;310:1248)</span></p>
<p class="bl"><span class="sbl">•</span> History: onset (sudden vs. gradual), quality, severity, location, duration, triggers, alleviating factors, positional component, hormonal triggers (menstruation), preceding trauma, associated sx (visual Δs, “floaters,” N/V, photophobia, focal neurologic sx), medications (analgesics), substance abuse (opioids, caffeine), personal/family hx of HA</p>
<p class="bl"><span class="sbl">•</span> General and neurologic exam (including funduscopic exam, visual fields)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Warning signs (should prompt neuroimaging)</b></p>
<p class="bl1"><i class="calibre3">Explosive onset</i> (vasc); “worst HA of my life” (SAH, RCVS); <i class="calibre3">meningismus</i> (SAH, infxn)</p>
<p class="bl1"><i class="calibre3">Positional:</i> lying &gt; standing (↑ ICP); <i class="calibre3">N/V</i> (↑ ICP; migraines)</p>
<p class="bl1"><i class="calibre3">Visual sx:</i> diplopia, blurring, ↓ acuity (GCA, glaucoma, ↑ ICP); <i class="calibre3">eye pain</i> (glaucoma, trigeminal autonomic cephalalgia, optic neuritis)</p>
<p class="bl1"><i class="calibre3">Abnl neuro exam</i> (struct. lesion, poss. in migraine); ↓ <i class="calibre3">consciousness</i> (± fever): infxn, ICH</p>
<p class="bl1"><i class="calibre3">Age</i> &gt;<i class="calibre3">50 y; immunosuppression</i> (CNS infections, PRES)</p>
<p class="bl"><span class="sbl">•</span> Imaging: CT or MRI; consider CTA (beading in vasculitis/RCVS/vasospasm), CTV/MRV</p>
<p class="bl"><span class="sbl">•</span> LP if ? SAH (✔ for xanthochromia), idiopathic intracranial HTN (✔opening press); image first!</p>
<p class="h">M<small class="calibre30">IGRAINE</small> <span class="s1">(<i class="calibre22">NEJM</i> 2017;377:553)</span></p>
<p class="h2a">Definition &amp; clinical manifestations <span class="s">(<i class="calibre3">Lancet</i> 2018;391:1315)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Epidemiology:</b> affects 15% of women and 6% of men; onset usually by 30 y</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Migraine w/o aura</b> (most common): <span class="s">≥</span>5 attacks lasting 4–72 h with both (a) N/V <i class="calibre3">or</i> photophobia &amp; phonophobia, and (b) <span class="s">≥</span>2 of following: unilateral, pulsating, mod–severe intensity, or aggravated by routine activity</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Migraine w/ aura:</b> <span class="s">≥</span>2 attacks w/: (a) aura defined as <span class="s">≥</span>1 fully reversible sx: visual Δs (flickering spots, visual loss), sensory sx (paresthesias, numbness), speech disturbance; <i class="calibre3">and</i> (b) unilateral progression of sx(s) over <span class="s">≥</span>5 but <span class="s">≤</span>60 min; <i class="calibre3">and</i> (c) HA w/in 60 min of aura</p>
<p class="bl"><span class="sbl">•</span> Aura may occur w/o HA (“acephalgic migraine”), must r/o TIA/stroke (typically rapid onset)</p>
<p class="bl"><span class="sbl">•</span> If motor weakness, consider <b class="calibre4">sporadic or familial hemiplegic migraine</b>: aura of reversible motor weakness (up to 24 h), a/w CACNA1A, ATP1A2, or SCN1A mutations</p>
<p class="bl"><span class="sbl">•</span> Precipitants: stress, foods (cheese, chocolate, MSG), fatigue, EtOH, menses, exercise</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Abortive Rx: 5-HT<sub class="calibre8">1</sub> agonists (triptans) effective if given early in migraine attack; contraindicated if motor aura, CAD, prior stroke. Also consider acetaminophen, caffeine, NSAIDs (ketorolac), steroids, Mg, metoclopramide, prochlorperazine, valproate, dihydroergotamine (caution if CAD, recent triptan use). <i class="calibre3">Avoid butalbital, opioids.</i></p>
<p class="bl"><span class="sbl">•</span> Prophylaxis: valproic acid, topiramate, β-blockers (propranolol first-line), TCAs, Mg, B2, botox, anti-CGRP &amp; receptor mAbs (femanezumab, erenumab; <i class="calibre3">NEJM</i> 2017;377:2113 &amp; 2123)</p>
<h2 class="ct"><a id="h118" class="calibre7"></a><a id="page_9-11" class="calibre7"></a><a href="part0002.html#rh130" class="calibre7">BACK AND SPINAL CORD DISEASE</a></h2>
<p class="h2a">Differential diagnosis of back pain</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Musculoskeletal:</b> involving spine (vertebra, facet joints), paraspinal muscles and ligaments, sacroiliac joint, or hip joint. Spondylolisthesis, vertebral fx, OA, inflam. spondyloarthritis (RA, ankylosing spondylitis, reactive, psoriatic), musculoligamentous “strain,” myofascial pain syndrome, trochanteric bursitis.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Spinal cord</b> (myelopathy)<b class="calibre4">/nerve root</b> (radiculopathy):</p>
<p class="bl1">Degenerative/traumatic: disc herniation, foraminal or lumbar stenosis, spondylolisthesis</p>
<p class="bl1">Neoplastic: lung, breast, prostate, RCC, thyroid, colon, multiple myeloma, lymphoma</p>
<p class="bl1">Infectious: osteomyelitis/discitis, epidural abscess, zoster, Lyme, CMV, HIV, spinal TB</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Referred pain from visceral disease:</b></p>
<p class="bl1">GI: PUD, cholelithiasis, pancreatitis, pancreatic cancer</p>
<p class="bl1">GU: pyelonephritis, nephrolithiasis, uterine or ovarian cancer, salpingitis</p>
<p class="bl1">Vascular: aortic dissection, leaking aortic aneurysm</p>
<p class="h2a">Initial evaluation <span class="s">(<i class="calibre3">Lancet</i> 2017;389:736)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">History:</b> location, radiation, trauma, wt loss, cancer hx, fever, immunocompromised, IV drug use, neurologic sx, saddle anesthesia, bowel/bladder sx (retention, incont.)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">General physical exam:</b> local tenderness, ROM, signs of infection or malignancy; paraspinal tenderness or spasm in musculoskeletal strain</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Signs of radiculopathy</b> (sharp/lancinating pain radiating into limb):</p>
<p class="bl1"><i class="calibre3">Spurling sign</i> (cervical radiculopathy): radicular pain w/ downward force to extended &amp; ipsilaterally rotated head; 30% Se, 93% Sp</p>
<p class="bl1"><i class="calibre3">Straight leg raise</i> (sciatica or lumbosacral radiculopathy): radicular pain at 30–70°; ipsilateral: 92% Se, 28% Sp; crossed (contralateral leg raised): 28% Se, 90% Sp</p>
<p class="bl1"><i class="calibre3">Patrick/FABER test</i> (sacroiliac joint syndrome): severe pain on hip external rotation; 70% Se, 100% Sp</p>
<p class="bl1"><i class="calibre3">Neurogenic claudication</i> in lumbar stenosis (see table on next page)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neurologic exam:</b> full motor (including sphincter tone), sensory (including perineal region; note dermatomal patterns), and reflexes including bulbocavernous, anal wink (S4), and cremasteric (L2)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Red flags:</b> upper motor neuron signs (hyperreflexia, upgoing toes), cauda equina or conus medullaris syndromes (saddle anesthesia, bowel or bladder dysfunction, reduced rectal tone, loss of sacral reflexes), pain at rest or at night</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Laboratory</b> (depending on suspicion): CBC w/ diff, ESR/CRP, Ca, PO<sub class="calibre8">4</sub>, CSF, BCx</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neuroimaging:</b> low yield if nonradiating pain, high false ⊕ rate (incidental spondylosis); depending on suspicion: X-rays, CT or CT myelography, MRI, bone scan</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">EMG/NCS:</b> may be useful to distinguish root/plexopathies from peripheral neuropathies</p>
<p class="h">S<small class="calibre30">PINAL</small> C<small class="calibre30">ORD</small> C<small class="calibre30">OMPRESSION</small></p>
<p class="h2a">Clinical features</p>
<p class="bl"><span class="sbl">•</span> Etiologies: <b class="calibre4">tumor</b> (vertebral mets, intradural meningioma/neurofibroma), <b class="calibre4">epidural abscess or hematoma</b>, vascular malformation (dural AV fistula), degenerative dis. (spondylosis)</p>
<p class="bl"><span class="sbl">•</span> Acute: flaccid paraparesis and absent reflexes (“spinal shock”)</p>
<p class="bl"><span class="sbl">•</span> Subacute–chronic: spastic paraparesis and hyperreflexia (upgoing toes ± ankle clonus)</p>
<p class="bl"><span class="sbl">•</span> Posterior column dysfunction in legs (loss of vibratory and/or proprioceptive sense)</p>
<p class="bl"><span class="sbl">•</span> Sensory loss below level of lesion (truncal level ± bilateral leg sx is clue for cord process)</p>
<p class="h2a">Evaluation &amp; treatment</p>
<p class="bl"><span class="sbl">•</span> Empiric spine immobilization (collar, board) for all trauma patients</p>
<p class="bl"><span class="sbl">•</span> STAT MRI (at and above clinical spinal level, with gadolinium) or CT myelogram</p>
<p class="bl"><span class="sbl">•</span> Emergent neurosurgical and/or neurology consultation. Urgent radiation therapy ± surgery for compression if due to metastatic disease <span class="s1r">(<i class="calibre3">Lancet Oncol</i> 2017;18:e720)</span>.</p>
<p class="bl"><span class="sbl">•</span> Empiric broad-spectrum antibiotics ± surgery if c/f epidural abscess</p>
<p class="bl"><span class="sbl">•</span> High-dose steroids depending on cause:</p>
<p class="bl1">Tumor: dexamethasone 16 mg/d IV (usually 4 mg q6h) with slow taper over wks</p>
<p class="bl1">Trauma: methylprednisolone 30 mg/kg IV over 15 min then 5.4 mg/kg/h × 24 h (if started w/in 3 h of injury) or × 48 h (if started 3–8 h after injury) <span class="s1r">(<i class="calibre3">Cochrane</i> 2012:CD001046)</span></p>
<p class="h">N<small class="calibre30">ERVE</small> R<small class="calibre30">OOT</small> C<small class="calibre30">OMPRESSION</small></p>
<p class="h2a">Clinical features <span class="s">(<i class="calibre3">NEJM</i> 2015;372:1240)</span></p>
<p class="bl"><span class="sbl">•</span> Radicular pain aggravated by activity (esp. bending, straining, coughing), relieved by lying</p>
<p class="bl"><span class="sbl">•</span> Sciatica = radicular pain radiating from buttocks down lateral aspect of leg, often to knee or lateral calf ± numbness and paresthesias radiating to lateral foot. Caused by compression of nerve roots, plexus, or sciatic nerve.</p>
<p class="h2a"><a id="page_9-12" class="calibre1"></a><span class="s2"><b class="calibre4">Pathophysiology</b></span></p>
<p class="bl"><span class="sbl">•</span> &lt;65 y: 90% from disc herniation. ≥65 y also w/ more degenerative contributors: ligamentous hypertrophy, osteophyte formation, facet arthropathy, neural foraminal narrowing</p>
<p class="bl"><span class="sbl">•</span> Spinal stenosis: central canal narrowing → root compression via direct impingement, CSF flow obstruction, vascular compromise</p>
<p class="imagef"><img src="../images/00138.jpeg" alt="" class="calibre2"/></p>
<p class="fn">Nb, lumbar disc protrusion tends to compress the nerve root that exits 1 vertebral level below the protrusion.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre17"/>
<col class="calibre17"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc">Neurogenic vs. Vascular Claudication</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabheadc">Features</p></td>
<td class="bg0-br"><p class="tabheadc">Neurogenic Claudication</p></td>
<td class="bg0-b"><p class="tabheadc">Vascular Claudication</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Cause</p></td>
<td class="bg0-br"><p class="tabc">Lumbar spinal stenosis (with nerve root compression)</p></td>
<td class="bg0-b"><p class="tabc">Peripheral artery disease</p>
<p class="tabc">(with limb ischemia)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Pain</p></td>
<td class="bg0-br"><p class="tabc">Radicular back/buttock pain</p>
<p class="tabc">Radiating down legs</p></td>
<td class="bg0-b"><p class="tabc">Cramping leg pain</p>
<p class="tabc">Mostly in calves; radiating up legs</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Worse with</p></td>
<td class="bg0-br"><p class="tabc">Walking &amp; standing</p>
<p class="tabc">Hyperextension/lying prone</p></td>
<td class="bg0-b"><p class="tabc">Walking</p>
<p class="tabc">Biking</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Better with</p></td>
<td class="bg0-br"><p class="tabc">Bending forward, sitting</p></td>
<td class="bg0-b"><p class="tabc">Rest (standing or sitting)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Other sx</p></td>
<td class="bg0-br"><p class="tabc">Numbness/paresthesias</p></td>
<td class="bg0-b"><p class="tabc">Pale, cool extremity</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Exam</p></td>
<td class="bg0-br"><p class="tabc">± Focal weakness, ↓ reflexes</p>
<p class="tabc">↓ Lumbar extension</p>
<p class="tabc">Preserved pulses</p></td>
<td class="bg0-b"><p class="tabc">Diminished/absent pulses</p>
<p class="tabc">(dorsalis pedis/posterior tibialis) Pallor</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Diagnostic studies</p></td>
<td class="bg0-br"><p class="tabc">MRI lumbar spine</p>
<p class="tabc">CT myelogram (if no MRI)</p>
<p class="tabc">EMG/NCS</p></td>
<td class="bg0-b"><p class="tabc">Arterial Doppler studies</p>
<p class="tabc">Ankle-brachial index (ABI) Arteriography</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc">Treatment</p></td>
<td class="bg0-r"><p class="tabc">PT (flexion exercise), NSAIDs,</p>
<p class="tabc">epidural steroid injections (ESI)</p>
<p class="tabc">Surgery (if other Rx fails)</p></td>
<td class="bg"><p class="tabc">Modify vascular risk factors, exercise rehab, antiplatelet Rx, revascularization</p></td>
</tr>
</table>
<p class="tsr">Nb, diagnosis complicated by overlap between presentations &amp; possibility of both diagnoses in the same patient. (<i class="calibre3">NEJM</i> 2007;356:1241 &amp; 2008;358:818)</p>
<p class="h2a">Evaluation &amp; treatment of nerve root compression <span class="s">(<i class="calibre3">NEJM</i> 2016;374:1763)</span></p>
<p class="bl"><span class="sbl">•</span> MRI if sx not improved after 6 wk of conservative tx; if non-diagnostic, consider EMG/NCS</p>
<p class="bl"><span class="sbl">•</span> Conservative: avoid bending/lifting; soft collar (cervical radiculopathy); NSAIDs; muscle relaxants; lidocaine patch/ointment; Rx neuropathic pain (see “Peripheral Neuropathies”); physical therapy. Insufficient evidence to recommend oral steroids.</p>
<p class="bl"><span class="sbl">•</span> Avoid opiates when possible; risks outweigh benefits in noncancerous back pain</p>
<p class="bl"><span class="sbl">•</span> Spinal epidural steroid injections (ESI): limited short-term relief of refractory radicular pain</p>
<p class="bl"><span class="sbl">•</span> Surgery: cord compression or cauda equina syndrome; progressive motor dysfunction; bowel/bladder dysfunction; failure to respond to conservative Rx after 3 mo</p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../k34gmbu8.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-74951b69f9a94472af57c47504abb1f1">Title Page</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-74951b69f9a94472af57c47504abb1f1">Copyright Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-74951b69f9a94472af57c47504abb1f1">Contents</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-74951b69f9a94472af57c47504abb1f1">Contributing Authors</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-74951b69f9a94472af57c47504abb1f1">Foreword</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-74951b69f9a94472af57c47504abb1f1">Preface</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-74951b69f9a94472af57c47504abb1f1">Cardiology</a>
      <ul>
        <li>
          <a href="part0006.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0006.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0006.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0006.html#h4">Coronary Angiography and Revascularization</a>
        </li>
        <li>
          <a href="part0006.html#h5">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h6">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0006.html#h7">Heart Failure</a>
        </li>
        <li>
          <a href="part0006.html#h8">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0006.html#h9">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0006.html#h10">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0006.html#h11">Hypertension</a>
        </li>
        <li>
          <a href="part0006.html#h12">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0006.html#h13">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h14">Arrhythmias</a>
        </li>
        <li>
          <a href="part0006.html#h15">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0006.html#h16">Syncope</a>
        </li>
        <li>
          <a href="part0006.html#h17">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0006.html#h18">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0006.html#h19">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0007.html#6LJU0-74951b69f9a94472af57c47504abb1f1">Pulmonary</a>
      <ul>
        <li>
          <a href="part0007.html#h20">Dyspnea</a>
        </li>
        <li>
          <a href="part0007.html#h21">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0007.html#h22">Asthma</a>
        </li>
        <li>
          <a href="part0007.html#h23">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0007.html#h24">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0007.html#h25">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0007.html#h26">Hemoptysis</a>
        </li>
        <li>
          <a href="part0007.html#h27">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0007.html#h28">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0007.html#h29">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0007.html#h30">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0007.html#h31">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0007.html#h32">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h33">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0007.html#h34">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0007.html#h35">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0007.html#h36">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0007.html#h37">Toxicology</a>
        </li>
        <li>
          <a href="part0007.html#h38">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-74951b69f9a94472af57c47504abb1f1">Gastroenterology</a>
      <ul>
        <li>
          <a href="part0008.html#h39">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0008.html#h40">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0008.html#h41">Diarrhea</a>
        </li>
        <li>
          <a href="part0008.html#h42">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0008.html#h43">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0008.html#h44">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0008.html#h45">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0008.html#h46">Pancreatitis</a>
        </li>
        <li>
          <a href="part0008.html#h47">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0008.html#h48">Hepatitis</a>
        </li>
        <li>
          <a href="part0008.html#h49">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0008.html#h50">Cirrhosis</a>
        </li>
        <li>
          <a href="part0008.html#h51">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0008.html#h52">Ascites</a>
        </li>
        <li>
          <a href="part0008.html#h53">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-74951b69f9a94472af57c47504abb1f1">Nephrology</a>
      <ul>
        <li>
          <a href="part0009.html#h54">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0009.html#h55">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h56">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h57">Renal Failure</a>
        </li>
        <li>
          <a href="part0009.html#h58">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h59">Urinalysis</a>
        </li>
        <li>
          <a href="part0009.html#h60">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-74951b69f9a94472af57c47504abb1f1">Hematology-Oncology</a>
      <ul>
        <li>
          <a href="part0010.html#h61">Anemia</a>
        </li>
        <li>
          <a href="part0010.html#h62">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0010.html#h63">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0010.html#h64">Coagulopathies</a>
        </li>
        <li>
          <a href="part0010.html#h65">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0010.html#h66">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0010.html#h67">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0010.html#h68">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0010.html#h69">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0010.html#h70">Leukemia</a>
        </li>
        <li>
          <a href="part0010.html#h71">Lymphoma</a>
        </li>
        <li>
          <a href="part0010.html#h72">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0010.html#h73">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0010.html#h74">Lung Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h75">Breast Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h76">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h77">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h78">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0010.html#h79">Hepatocellular Carcinoma (HCC)</a>
        </li>
        <li>
          <a href="part0010.html#h80">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0010.html#h81">Chemotherapy &amp; Immunotherapy Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-74951b69f9a94472af57c47504abb1f1">Infectious Diseases</a>
      <ul>
        <li>
          <a href="part0011.html#h82">Pneumonia</a>
        </li>
        <li>
          <a href="part0011.html#h83">Fungal Infections</a>
        </li>
        <li>
          <a href="part0011.html#h84">Infections in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0011.html#h85">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0011.html#h86">Soft Tissue and Bone Infections</a>
        </li>
        <li>
          <a href="part0011.html#h87">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0011.html#h88">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0011.html#h89">Tuberculosis</a>
        </li>
        <li>
          <a href="part0011.html#h90">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0011.html#h91">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0011.html#h92">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-74951b69f9a94472af57c47504abb1f1">Endocrinology</a>
      <ul>
        <li>
          <a href="part0012.html#h93">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h94">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h95">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h96">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h97">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0012.html#h98">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-74951b69f9a94472af57c47504abb1f1">Rheumatology</a>
      <ul>
        <li>
          <a href="part0013.html#h99">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0013.html#h100">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0013.html#h101">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0013.html#h102">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0013.html#h103">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0013.html#h104">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0013.html#h105">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0013.html#h106">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0013.html#h107">Vasculitis</a>
        </li>
        <li>
          <a href="part0013.html#h108">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0013.html#h109">Cryoglobulinemia</a>
        </li>
        <li>
          <a href="part0013.html#h110">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-74951b69f9a94472af57c47504abb1f1">Neurology</a>
      <ul>
        <li>
          <a href="part0014.html#h111">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0014.html#h112">Seizures</a>
        </li>
        <li>
          <a href="part0014.html#h113">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0014.html#h114">Dizziness</a>
        </li>
        <li>
          <a href="part0014.html#h115">Stroke</a>
        </li>
        <li>
          <a href="part0014.html#h116">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0014.html#h117">Headache</a>
        </li>
        <li>
          <a href="part0014.html#h118">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-74951b69f9a94472af57c47504abb1f1">Consults</a>
      <ul>
        <li>
          <a href="part0015.html#h119">Surgical Issues</a>
        </li>
        <li>
          <a href="part0015.html#h120">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0015.html#h121">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-74951b69f9a94472af57c47504abb1f1">Appendix</a>
      <ul>
        <li>
          <a href="part0016.html#h122">ICU Medications &amp; Treatment of Hypotension/Shock</a>
        </li>
        <li>
          <a href="part0016.html#h123">Antibiotics</a>
        </li>
        <li>
          <a href="part0016.html#h124">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-74951b69f9a94472af57c47504abb1f1">Abbreviations</a>
    </li>
    <li>
      <a href="part0018.html#H5A40-74951b69f9a94472af57c47504abb1f1">Index</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-74951b69f9a94472af57c47504abb1f1">Photo Inserts</a>
      <ul>
        <li>
          <a href="part0019.html#h125">Radiology</a>
        </li>
        <li>
          <a href="part0019.html#h126">Echocardiography &amp; Coronary Angiography</a>
        </li>
        <li>
          <a href="part0019.html#h127">Peripheral Blood Smears &amp; Leukemias</a>
        </li>
        <li>
          <a href="part0019.html#h128">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0022.html#KVCC0-74951b69f9a94472af57c47504abb1f1">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0013.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../k34gmbu8.html" class="calibreAHome">start
</a>

    
      <a href="part0015.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
